Tresiba (insulin degludec) stays active in your system for up to 42 hours after a single injection, making it the longest-lasting basal insulin currently available. Its half-life is approximately 25 hours, meaning it takes roughly five days after your last dose for the drug to be essentially cleared from your body. That extended timeline is by design and is what gives Tresiba its uniquely flat, steady blood-sugar-lowering effect.
How Tresiba Works Under the Skin
Tresiba’s unusually long duration comes from what happens the moment you inject it. The insulin molecules are engineered to link together into long chains called multi-hexamers, forming a small depot, or reservoir, just beneath the skin. From that depot, individual insulin molecules slowly peel off one at a time and enter the bloodstream at a steady rate.
Once those molecules reach the blood, they also attach to a protein called albumin, which acts like a slow-release carrier. This two-step process (gradual release from the depot, then albumin binding in the blood) is what stretches the drug’s activity well beyond a full day. The result is a smooth, nearly peakless insulin supply that closely mimics the low-level background insulin a healthy pancreas produces between meals and overnight.
Duration of Action vs. Total Clearance
These are two different questions people often blend together, and the distinction matters. Duration of action refers to how long the drug is actively lowering your blood sugar. For Tresiba, that window extends up to 42 hours from a single dose. Total clearance is how long traces of the drug remain detectable in your body, which is considerably longer.
With a half-life of about 25 hours, it takes roughly five half-lives for a drug to drop to negligible levels. That puts full clearance of Tresiba at roughly four to five days after your last injection. During those final days, the remaining amount is small and steadily shrinking, but it’s still present. This is important to keep in mind if you’re switching to a different insulin or adjusting your regimen, because overlapping effects can temporarily increase your risk of low blood sugar.
Steady State and Daily Dosing
Because Tresiba lasts so long, each new daily injection overlaps with the tail end of the previous dose. After about three to four consecutive days of once-daily dosing, these overlapping doses reach a predictable balance called steady state. At steady state, the amount entering your system each day roughly equals the amount being cleared, giving you a consistent level of background insulin around the clock.
This overlap is also why Tresiba allows more dosing flexibility than other long-acting insulins. The label permits a minimum of 8 hours between doses, so if you normally inject at 9 PM but one night can’t take it until 1 AM, the extended tail from your previous dose keeps you covered. That said, consistency still produces the most predictable blood sugar control.
How Tresiba Compares to Other Basal Insulins
Tresiba’s 42-hour duration is noticeably longer than its main competitors. Lantus (insulin glargine U-100) lasts up to 24 hours, and the concentrated version, Toujeo (glargine U-300), extends to roughly 36 hours. Levemir (insulin detemir) has an even shorter window, typically ranging from 12 to 24 hours depending on the dose.
In practical terms, this means Tresiba has the longest tail of any basal insulin on the market. If you miss a dose of Lantus, you may notice rising blood sugar within half a day. With Tresiba, you have a much wider buffer before coverage drops off significantly. The tradeoff is that if you need to stop the insulin quickly (for example, because of repeated low blood sugars), its effects take longer to fade.
Kidney and Liver Disease
Because insulin is partly cleared by the kidneys and liver, it’s reasonable to wonder whether impaired organ function would make Tresiba linger longer. Clinical studies compared Tresiba’s behavior in people with normal organ function to those with mild, moderate, and severe kidney disease, as well as varying degrees of liver impairment.
For kidney disease, total drug exposure was modestly higher (roughly 10 to 27% depending on severity) in people with impaired kidney function, but the FDA concluded there was no clinically meaningful difference in how the drug behaved. People on hemodialysis showed clearance rates similar to those with normal kidneys. For liver disease, there was no measurable difference at all, even in people with severe impairment. In short, neither condition changes how long Tresiba stays in your system in a way that would require a fundamentally different approach, though closer blood sugar monitoring is always reasonable when organ function is compromised.
What This Means if You Stop Taking Tresiba
If you take your last dose and stop, expect blood-sugar-lowering effects to taper gradually over the next 42 hours or so, then fade over the following two to three days as the remaining drug clears. You won’t lose all basal coverage the moment you skip a dose, but you also won’t have full coverage either. The decline is gradual, not a cliff.
If you’re transitioning to a different long-acting insulin, the overlap period requires careful attention to dosing. Your prescriber will typically have you start the new insulin at a reduced dose or time the switch so the two drugs don’t stack on top of each other and drive blood sugar dangerously low. The key number to keep in mind: meaningful amounts of Tresiba remain in your body for roughly four to five days after the final injection.